Semaglutide and cardio-renal protection: Mechanistic insights from FLOW, SELECT and the NHE3 paradox

Diabetic kidney disease remains a leading cause of end-stage renal disease despite contemporary RAAS blockade and SGLT2 inhibition, underscoring the need for complementary therapies. This review critically evaluates the mechanistic basis for semaglutide’s cardio-renal protection, a GLP-1 receptor agonist with emerging nephroprotective effects. The FLOW trial demonstrated a 24% reduction (HR 0.76) in the primary composite kidney outcome and slowed annual eGFR decline by 1.16 mL/min/1.73m ² in type 2 diabetes with chronic kidney disease. The SELECT trial demonstrated a 20% reduction in major cardiovascular events in non-diabetic individuals with obesity and established atherosclerotic disease, a benefit preserved in a normoglycemic subgroup, with pre-specified secondary evidence supporting renal benefit. Despite this clinical outcome data, key mechanisms remain incompletely understood: natriuresis is reproducible, yet proximal tubular GLP-1 receptor expression is uncertain, and no proposed pathway has been confirmed in human tissue. To address this gap, we present an evidence-tier framework separating clinical from mechanistic evidence and ranking pathways by evidentiary strength across organ systems. Using this framework, hemodynamic mechanisms are identified as the best-supported explanation for renal protection based on current clinical evidence, though direct confirmation in human renal tissue remains lacking for the NHE3 pathway and competing natriuretic mechanisms. SELECT’s normoglycemic subgroup provides one of the strongest clinical constraints on proposed mechanisms: any proposed pathway must be capable of operating without overt hyperglycemia, though not necessarily of broader metabolic change. Closing the gap between clinical outcome data and mechanistic understanding represents a major unresolved question in cardio-renal pharmacology.